To reinforce the values of Altilix® supplementation in improving hepatic function in NAFLD patients, there is in our data the enhanced AST/ALT ratio, a reduction in both AST and ALT and FLI serum levels after 6 months of supplemented subjects compared with the placebo group, suggesting that subjects at high risk of developing hepatic complications of MetS could benefit from the mentioned supplementation. Here, GPT is linked to metabolic dysfunction-associated steatotic liver disease.